DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization - PubMed (original) (raw)

DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization

S Y Shieh et al. EMBO J. 1999.

Abstract

Upon DNA damage, p53 has been shown to be modified at a number of N-terminal phosphorylation sites including Ser15 and -33. Here we show that phosphorylation is induced as well at a novel site, Ser20. Phosphorylation at Ser15, -20 and -33 can occur within minutes of DNA damage. Interestingly, while the DNA-binding activities of p53 appear to be dispensable, efficient phosphorylation at these three sites requires the tetramerization domain of p53. Substitution of an artificial tetramerization domain for this region also permits phosphorylation at the N-terminus, suggesting that oligomerization is important for DNA damage-induced signalling to p53.

PubMed Disclaimer

Similar articles

• Structured DNA promotes phosphorylation of p53 by DNA-dependent protein kinase at serine 9 and threonine 18.
  Soubeyrand S, Schild-Poulter C, Haché RJ. Soubeyrand S, et al. Eur J Biochem. 2004 Sep;271(18):3776-84. doi: 10.1111/j.1432-1033.2004.04319.x. Eur J Biochem. 2004. PMID: 15355354
• Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers.
  Craig AL, Burch L, Vojtesek B, Mikutowska J, Thompson A, Hupp TR. Craig AL, et al. Biochem J. 1999 Aug 15;342 ( Pt 1)(Pt 1):133-41. Biochem J. 1999. PMID: 10432310 Free PMC article.
• Signaling to p53: breaking the posttranslational modification code.
  Appella E, Anderson CW. Appella E, et al. Pathol Biol (Paris). 2000 Apr;48(3):227-45. Pathol Biol (Paris). 2000. PMID: 10858956 Review.
• Protein kinase CK1 is a p53-threonine 18 kinase which requires prior phosphorylation of serine 15.
  Dumaz N, Milne DM, Meek DW. Dumaz N, et al. FEBS Lett. 1999 Dec 17;463(3):312-6. doi: 10.1016/s0014-5793(99)01647-6. FEBS Lett. 1999. PMID: 10606744
• The role of tetramerization in p53 function.
  Chène P. Chène P. Oncogene. 2001 May 10;20(21):2611-7. doi: 10.1038/sj.onc.1204373. Oncogene. 2001. PMID: 11420672 Review.

Cited by

• Experimental Insights into the Interplay between Histone Modifiers and p53 in Regulating Gene Expression.
  Kim HM, Zheng X, Lee E. Kim HM, et al. Int J Mol Sci. 2023 Jul 3;24(13):11032. doi: 10.3390/ijms241311032. Int J Mol Sci. 2023. PMID: 37446210 Free PMC article. Review.
• Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition.
  Hassel JC, Zimmer L, Sickmann T, Eigentler TK, Meier F, Mohr P, Pukrop T, Roesch A, Vordermark D, Wendl C, Gutzmer R. Hassel JC, et al. Cancers (Basel). 2023 Jun 30;15(13):3448. doi: 10.3390/cancers15133448. Cancers (Basel). 2023. PMID: 37444558 Free PMC article. Review.
• p53-Dependent Cytoprotective Mechanisms behind Resistance to Chemo-Radiotherapeutic Agents Used in Cancer Treatment.
  Krishnaraj J, Yamamoto T, Ohki R. Krishnaraj J, et al. Cancers (Basel). 2023 Jun 28;15(13):3399. doi: 10.3390/cancers15133399. Cancers (Basel). 2023. PMID: 37444509 Free PMC article. Review.
• The MDMX Acidic Domain Uses Allovalency to Bind Both p53 and MDMX.
  Fenton M, Borcherds W, Chen L, Anbanandam A, Levy R, Chen J, Daughdrill G. Fenton M, et al. J Mol Biol. 2022 Nov 30;434(22):167844. doi: 10.1016/j.jmb.2022.167844. Epub 2022 Sep 29. J Mol Biol. 2022. PMID: 36181774 Free PMC article.
• Post-Translational Modifications of p53 in Ferroptosis: Novel Pharmacological Targets for Cancer Therapy.
  Zhang L, Hou N, Chen B, Kan C, Han F, Zhang J, Sun X. Zhang L, et al. Front Pharmacol. 2022 May 24;13:908772. doi: 10.3389/fphar.2022.908772. eCollection 2022. Front Pharmacol. 2022. PMID: 35685623 Free PMC article. Review.

References

1. 1. Oncogene. 1995 May 4;10(9):1865-8 - PubMed
2. 1. Cancer Res. 1995 Jun 1;55(11):2410-7 - PubMed
3. 1. Nat Struct Biol. 1994 Dec;1(12):877-90 - PubMed
4. 1. Oncogene. 1995 Jun 1;10(11):2095-101 - PubMed
5. 1. Adv Cancer Res. 1995;66:143-80 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Nature Publishing Group
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations

• Molecular Biology Databases

  • GlyGen glycoinformatics resource
  • PhosphoSitePlus

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal